Trial Profile
6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2021
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- 01 Apr 2009 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Actual patient number (454) added as reported by ClinicalTrials.gov.
- 16 May 2007 Status changed from 'recruiting' to 'completed'